These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials? Grahnén A; Karlsson MO Clin Pharmacokinet; 2001; 40(5):317-25. PubMed ID: 11432535 [TBL] [Abstract][Full Text] [Related]
4. The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Sanathanan LP; Peck CC Control Clin Trials; 1991 Dec; 12(6):780-94. PubMed ID: 1665119 [TBL] [Abstract][Full Text] [Related]
5. Weighted re-randomization tests for minimization with unbalanced allocation. Han B; Yu M; McEntegart D Pharm Stat; 2013; 12(4):243-53. PubMed ID: 23760923 [TBL] [Abstract][Full Text] [Related]
6. Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials. Lledó-García R; Hennig S; Karlsson MO Clin Pharmacol Ther; 2009 Jul; 86(1):62-9. PubMed ID: 19339964 [TBL] [Abstract][Full Text] [Related]
7. A comparison of the statistical power of different methods for the analysis of cluster randomization trials with binary outcomes. Austin PC Stat Med; 2007 Aug; 26(19):3550-65. PubMed ID: 17238238 [TBL] [Abstract][Full Text] [Related]
8. The influence of underlying assumptions on evaluating the relative merits of concentration-controlled and dose-controlled trials. Lledó-García R; Hennig S; Karlsson MO Clin Pharmacol Ther; 2009 Jul; 86(1):70-6. PubMed ID: 19279565 [TBL] [Abstract][Full Text] [Related]
10. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials. Pond GR; Abbasi S Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687 [TBL] [Abstract][Full Text] [Related]
11. The impact of randomization on the analysis of clinical trials. Rosenkranz GK Stat Med; 2011 Dec; 30(30):3475-87. PubMed ID: 21953285 [TBL] [Abstract][Full Text] [Related]
12. Methodological issues of randomized controlled trials for the evaluation of reproductive health interventions. Villar J; Carroli G Prev Med; 1996; 25(3):365-75. PubMed ID: 8781015 [TBL] [Abstract][Full Text] [Related]
13. Statistical methods for a three-period crossover design in which high dose cannot be used first. Peace KE; Koch GG J Biopharm Stat; 1993 Mar; 3(1):103-16. PubMed ID: 8485531 [TBL] [Abstract][Full Text] [Related]
14. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials. Xie F; Ji Y; Tremmel L Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247 [TBL] [Abstract][Full Text] [Related]
15. How to deal with multiple treatment or dose groups in randomized clinical trials? Hothorn LA Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286 [TBL] [Abstract][Full Text] [Related]
16. Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach. Bajard A; Chabaud S; Pérol D; Boissel JP; Nony P Contemp Clin Trials; 2009 Sep; 30(5):400-10. PubMed ID: 19576298 [TBL] [Abstract][Full Text] [Related]
17. Weighting in instrumental variables and G-estimation. Joffe MM; Brensinger C Stat Med; 2003 Apr; 22(8):1285-303. PubMed ID: 12687655 [TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trials with a prospective control. Jung SH Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688 [TBL] [Abstract][Full Text] [Related]
19. Current issues with covariate adjustment in the analysis of data from randomized controlled trials. Alemayehu D Am J Ther; 2011; 18(2):153-7. PubMed ID: 19797942 [TBL] [Abstract][Full Text] [Related]